Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incannex Healthcare (IXHL) Share-based Compensation (2021 - 2025)

Incannex Healthcare's Share-based Compensation history spans 3 years, with the latest figure at -$2.3 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 423.91% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.2 million, a 169.9% decrease, with the full-year FY2025 number at $2.6 million, down 70.78% from a year prior.
  • Share-based Compensation hit -$2.3 million in Q4 2025 for Incannex Healthcare, up from -$2.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for IXHL hit a ceiling of $3.7 million in Q4 2023 and a floor of -$2.6 million in Q3 2025.
  • Historically, Share-based Compensation has averaged $484500.0 across 3 years, with a median of $107500.0 in 2023.
  • The widest YoY moves for Share-based Compensation: up 61.17% in 2025, down 472.11% in 2025.
  • Tracing IXHL's Share-based Compensation over 3 years: stood at $3.7 million in 2023, then plummeted by 111.85% to -$435000.0 in 2024, then tumbled by 423.91% to -$2.3 million in 2025.
  • Business Quant data shows Share-based Compensation for IXHL at -$2.3 million in Q4 2025, -$2.6 million in Q3 2025, and $1.3 million in Q2 2025.